Reduction of serum VEGF and IL-6 levels in patients with metastatic breast cancer: Results of a study of PTC299, an oral inhibitor of tumor VEGF synthesis, and aromatase inhibitors.
M. N. Dickler
Research Funding - PTC Therapeutics
B. P. Schneider
Research Funding - PTC Therapeutics
M. Volm
Research Funding - PTC Therapeutics
J. L. Speyer
Research Funding - PTC Therapeutics
Y. Novik
Research Funding - PTC Therapeutics
L. A. Callahan
Employment or Leadership Position - PTC Therapeutics
Stock Ownership - PTC Therapeutics
Research Funding - PTC Therapeutics
C. H. Darby
Employment or Leadership Position - PTC Therapeutics
Stock Ownership - PTC Therapeutics
Research Funding - PTC Therapeutics
J. Barth
Employment or Leadership Position - PTC Therapeutics
Stock Ownership - PTC Therapeutics
Research Funding - PTC Therapeutics
G. L. Elfring
Employment or Leadership Position - PTC Therapeutics
Stock Ownership - PTC Therapeutics
Research Funding - PTC Therapeutics
A. Ogden
Employment or Leadership Position - PTC Therapeutics
Stock Ownership - PTC Therapeutics
Research Funding - PTC Therapeutics
A. Tiersten
Research Funding - PTC Therapeutics